PE20141035A1 - Composiciones y metodos para tratar el cancer usando el inhibidor de pi3kbeta y el inhibidor de la via de mapk, incluidos los inhibidores de mek y raf - Google Patents
Composiciones y metodos para tratar el cancer usando el inhibidor de pi3kbeta y el inhibidor de la via de mapk, incluidos los inhibidores de mek y rafInfo
- Publication number
- PE20141035A1 PE20141035A1 PE2014000346A PE2014000346A PE20141035A1 PE 20141035 A1 PE20141035 A1 PE 20141035A1 PE 2014000346 A PE2014000346 A PE 2014000346A PE 2014000346 A PE2014000346 A PE 2014000346A PE 20141035 A1 PE20141035 A1 PE 20141035A1
- Authority
- PE
- Peru
- Prior art keywords
- inhibitor
- compositions
- methods
- treating cancer
- pi3kbeta
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 102000043136 MAP kinase family Human genes 0.000 title abstract 2
- 108091054455 MAP kinase family Proteins 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 229940125520 PI3Kβ inhibitor Drugs 0.000 title 1
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 abstract 1
- 108091007960 PI3Ks Proteins 0.000 abstract 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000009929 raf Kinases Human genes 0.000 abstract 1
- 108010077182 raf Kinases Proteins 0.000 abstract 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 abstract 1
- 229950010746 selumetinib Drugs 0.000 abstract 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 abstract 1
- 229960003862 vemurafenib Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11306172A EP2570127A1 (en) | 2011-09-16 | 2011-09-16 | Compositions and methods for treating cancer using PI3KB beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20141035A1 true PE20141035A1 (es) | 2014-09-04 |
Family
ID=46851503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2014000346A PE20141035A1 (es) | 2011-09-16 | 2012-09-14 | Composiciones y metodos para tratar el cancer usando el inhibidor de pi3kbeta y el inhibidor de la via de mapk, incluidos los inhibidores de mek y raf |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20140275078A1 (enExample) |
| EP (2) | EP2570127A1 (enExample) |
| JP (1) | JP2014530181A (enExample) |
| KR (1) | KR20140062143A (enExample) |
| CN (1) | CN103889418A (enExample) |
| AR (1) | AR087902A1 (enExample) |
| AU (1) | AU2012307309A1 (enExample) |
| BR (1) | BR112014005839A2 (enExample) |
| CA (1) | CA2847091A1 (enExample) |
| CL (1) | CL2014000606A1 (enExample) |
| CO (1) | CO6910192A2 (enExample) |
| CR (1) | CR20140102A (enExample) |
| DO (1) | DOP2014000046A (enExample) |
| EA (1) | EA201490638A1 (enExample) |
| EC (1) | ECSP14013244A (enExample) |
| GT (1) | GT201400038A (enExample) |
| IL (1) | IL231212A0 (enExample) |
| MA (1) | MA35615B1 (enExample) |
| MX (1) | MX2014003223A (enExample) |
| NI (1) | NI201400020A (enExample) |
| PE (1) | PE20141035A1 (enExample) |
| PH (1) | PH12014500536A1 (enExample) |
| SG (1) | SG11201400380XA (enExample) |
| TN (1) | TN2014000086A1 (enExample) |
| UY (1) | UY34341A (enExample) |
| WO (1) | WO2013037943A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9913844B2 (en) | 2013-03-21 | 2018-03-13 | Novartis Ag | Combination therapy |
| US20160030440A1 (en) * | 2013-04-05 | 2016-02-04 | Sanofi | Anti-tumoral composition comprising a pi3kbeta-selective inhibitor and a pi3kalpha-selective inhibitor |
| WO2015051252A1 (en) * | 2013-10-03 | 2015-04-09 | Duke University | Compositions and methods for treating cancer with jak2 activity |
| WO2015161230A1 (en) * | 2014-04-19 | 2015-10-22 | Massachusetts Institute Of Technology | Methods of reducing kinase inhibitor resistance |
| US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| KR101950094B1 (ko) | 2017-07-28 | 2019-02-19 | 이성재 | 보릿대 공예품 제작방법 |
| CN113440616A (zh) * | 2020-03-25 | 2021-09-28 | 上海科州药物研发有限公司 | Ras或raf突变型癌症的联合疗法 |
| CN120204228B (zh) * | 2025-04-17 | 2026-01-30 | 重庆医科大学附属第一医院 | 化合物或其盐在制备癌症治疗药物中的用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG2013013339A (en) | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| MY153898A (en) | 2005-06-22 | 2015-04-15 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| FR2951169B1 (fr) * | 2009-10-09 | 2011-12-02 | Sanofi Aventis | Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) |
| PE20120640A1 (es) | 2009-07-02 | 2012-06-09 | Sanofi Sa | Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparacion y su utilizacion farmaceutica como inhibidores de fosforilacion de akt (pkb) |
-
2011
- 2011-09-16 EP EP11306172A patent/EP2570127A1/en not_active Ceased
-
2012
- 2012-09-14 BR BR112014005839A patent/BR112014005839A2/pt not_active IP Right Cessation
- 2012-09-14 WO PCT/EP2012/068072 patent/WO2013037943A1/en not_active Ceased
- 2012-09-14 MX MX2014003223A patent/MX2014003223A/es not_active Application Discontinuation
- 2012-09-14 AU AU2012307309A patent/AU2012307309A1/en not_active Abandoned
- 2012-09-14 PE PE2014000346A patent/PE20141035A1/es not_active Application Discontinuation
- 2012-09-14 CA CA2847091A patent/CA2847091A1/en not_active Abandoned
- 2012-09-14 US US14/343,935 patent/US20140275078A1/en not_active Abandoned
- 2012-09-14 JP JP2014530237A patent/JP2014530181A/ja not_active Abandoned
- 2012-09-14 EP EP12759137.8A patent/EP2755653A1/en not_active Withdrawn
- 2012-09-14 CN CN201280051036.1A patent/CN103889418A/zh active Pending
- 2012-09-14 PH PH1/2014/500536A patent/PH12014500536A1/en unknown
- 2012-09-14 SG SG11201400380XA patent/SG11201400380XA/en unknown
- 2012-09-14 EA EA201490638A patent/EA201490638A1/ru unknown
- 2012-09-14 KR KR1020147009655A patent/KR20140062143A/ko not_active Withdrawn
- 2012-09-17 UY UY0001034341A patent/UY34341A/es not_active Application Discontinuation
- 2012-09-17 AR ARP120103421A patent/AR087902A1/es unknown
-
2014
- 2014-02-27 CR CR20140102A patent/CR20140102A/es unknown
- 2014-02-27 IL IL231212A patent/IL231212A0/en unknown
- 2014-02-28 TN TNP2014000086A patent/TN2014000086A1/en unknown
- 2014-03-03 GT GT201400038A patent/GT201400038A/es unknown
- 2014-03-04 DO DO2014000046A patent/DOP2014000046A/es unknown
- 2014-03-13 CL CL2014000606A patent/CL2014000606A1/es unknown
- 2014-03-14 CO CO14055689A patent/CO6910192A2/es unknown
- 2014-03-14 EC ECSP14013244 patent/ECSP14013244A/es unknown
- 2014-03-14 NI NI201400020A patent/NI201400020A/es unknown
- 2014-04-10 MA MA36908A patent/MA35615B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201490638A1 (ru) | 2014-08-29 |
| CA2847091A1 (en) | 2013-03-21 |
| JP2014530181A (ja) | 2014-11-17 |
| EP2755653A1 (en) | 2014-07-23 |
| MA35615B1 (fr) | 2014-11-01 |
| TN2014000086A1 (en) | 2015-07-01 |
| AR087902A1 (es) | 2014-04-23 |
| ECSP14013244A (es) | 2014-07-31 |
| IL231212A0 (en) | 2014-04-30 |
| WO2013037943A8 (en) | 2013-07-18 |
| CN103889418A (zh) | 2014-06-25 |
| NI201400020A (es) | 2014-04-23 |
| CR20140102A (es) | 2014-05-07 |
| AU2012307309A1 (en) | 2014-04-03 |
| US20140275078A1 (en) | 2014-09-18 |
| WO2013037943A1 (en) | 2013-03-21 |
| UY34341A (es) | 2013-04-05 |
| EP2570127A1 (en) | 2013-03-20 |
| KR20140062143A (ko) | 2014-05-22 |
| PH12014500536A1 (en) | 2019-08-07 |
| MX2014003223A (es) | 2014-06-05 |
| CL2014000606A1 (es) | 2014-11-07 |
| BR112014005839A2 (pt) | 2017-03-28 |
| CO6910192A2 (es) | 2014-03-31 |
| DOP2014000046A (es) | 2014-07-15 |
| SG11201400380XA (en) | 2014-04-28 |
| GT201400038A (es) | 2014-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR122743A2 (es) | Composición farmacéutica de antagonistas de unión al eje pd-1 e inhibidores de mek | |
| SV2010003673A (es) | Compuestos heterociclicos novedosos y usos de los mismos | |
| AR102463A1 (es) | Inhibidor de cinasa aurora a | |
| MX384721B (es) | Tratamiento del cáncer usando combinaciones de inhibidores de erk y raf. | |
| CL2017000469A1 (es) | Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1 | |
| CL2011000527A1 (es) | Compuestos derivados de benzofurano; composicion farmaceutica que los comprende;y su uso en el tratamiento de la hepatitis c. | |
| CL2011000191A1 (es) | Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer. | |
| CL2016000241A1 (es) | Formulación de inhibidores de la syk. | |
| BR112015020466A8 (pt) | inibidores de cdc7, seus usos, e composição farmacêutica | |
| CL2012002319A1 (es) | Compuestos derivados de amino-tienopirimidinas que contienen un grupo alquilo sustituido, inhibidores de mnk| o mnk2; composición farmacéutica; y su uso para la profilaxis o la terapia de enfermedades metabólicas, trastornos hematopoyéticos, enfermedades neurodegenerativas, cáncer, entre otras. | |
| AR087107A1 (es) | Compuesto inhibidor de la señalizacion de la trayectoria notch | |
| CL2012003110A1 (es) | Compuestos derivados de n-[(2-oxo-1,2-dihidro-3-piridinil)metil]-1h-indol-4-carboxamida, inhibidores de ezh2; composicion farmaceutica que los contiene; utiles en el tratamiento del cancer seleccionado del grupo que consiste de cerebro (gliomas) glioblastomas, leucemias y linfomas, y trastornos mediados por la inhibicion del ezh2. | |
| NI201300038A (es) | Composiciones y métodos para el tratamiento de la mielofibrosis | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| AR092899A1 (es) | Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| CL2016000379A1 (es) | Composiciones y métodos terapéuticos para reducción acelerada de plagas | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| CL2014000606A1 (es) | Combinacion farmaceutica que comprende al compuesto 2-{2-[(2s)-2-metil-2,3-dihidro-1h-indol-1-il]-2-oxoetil}-6-(morfolin-4-il)pirimidin-4-(3h)-ona y al menos un inhibidor de la via de mapk; composicion farmaceutica; kit farmaceutico; su uso en el tratamiento del cancer. | |
| DOP2013000131A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek | |
| CO2022008690A2 (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso | |
| MX2016014261A (es) | Uso de acido 1,3-propandisulfonico o sales farmaceuticamente aceptables del mismo para el tratamiento de sarcoidosis. | |
| PE20142020A1 (es) | Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek | |
| NI201300052A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek | |
| NZ764041A (en) | Use of 1,3-propanedisulfonic acid or pharmaceutically acceptable salts thereof for the treatment of sarcoidosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |